List of Figures
Figure 1: Global Sales Forecast by Country for Crohn’s Disease in 2019 and 2029
Figure 2: Analysis of the Company Portfolio Gap in Crohn’s Disease During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Crohn’s Disease During the Forecast Period
Figure 4: Pathophysiology of Crohn’s Disease
Figure 5: 8MM, Diagnosed Incidence of CD, Men and Women, Cases per 100,000 Population, All Ages, 2019
Figure 6: 8MM, Diagnosed Prevalence of CD, Men and Women, %, All Ages, 2019
Figure 7: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of CD
Figure 8: 8MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of CD
Figure 9: 8MM, Diagnosed Incident Cases of CD, N, Both Sexes, All Ages, 2019
Figure 10: 8MM, Diagnosed Incident Cases of CD by Age, N, Both Sexes, 2019
Figure 11: 8MM, Diagnosed Incident Cases of CD by Sex, N, All Ages, 2019
Figure 12: 8MM, Diagnosed Prevalent Cases of CD, N, Both Sexes, All Ages, 2019
Figure 13: 8MM, Diagnosed Prevalent Cases of CD by Age, N, Both Sexes, 2019
Figure 14: 8MM, Diagnosed Prevalent Cases of CD by Sex, N, All Ages, 2019
Figure 15: 8MM, Diagnosed Prevalent Cases of CD by Severity, N, All Ages, 2019
Figure 16: 8MM, Diagnosed Prevalent Cases of Fistulizing CD by Severity, N, All Ages, 2019
Figure 17: Unmet Needs and Opportunities in Crohn’s Disease
Figure 18: Overview of the Development Pipeline in Crohn’s Disease
Figure 19: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for Crohn’s Disease in the 8MM During the Forecast Period
Figure 20: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Crohn’s Disease During the Forecast Period
Figure 21: Analysis of the Company Portfolio Gap in Crohn’s Disease During the Forecast Period
Figure 22: Global (8MM) Sales Forecast by Country for Crohn’s Disease in 2019 and 2029
Figure 23: Sales Forecast by Class for Crohn’s Disease in the US in 2019 and 2029
Figure 24: Sales Forecast by Class for Crohn’s Disease in the 5EU in 2019 and 2029
Figure 25: Sales Forecast by Class for Crohn’s Disease in Japan in 2019 and 2029
Figure 26: Sales Forecast by Class for Crohn’s Disease in Canada in 2019 and 2029

 

List of Tables
Table 1: Crohn’s Disease: Key Metrics in the 8MM
Table 2: Types of Crohn’s Disease
Table 3: Crohn’s Disease Severities
Table 4: Risk Factors and Comorbidities for CD
Table 5: Treatment Guidelines for Crohn’s Disease
Table 6: Country Profile - US
Table 7: Country Profile - 5EU
Table 8: Country Profile - Japan
Table 9: Country Profile - Canada
Table 10: Leading Treatments for Crohn’s Disease, 2019
Table 11: Comparison of Therapeutic Classes in Development for Crohn’s Disease, 2019-2029
Table 12: Janssen’s Disease Portfolio Assessment, 2020
Table 13: AbbVie’s Disease Portfolio Assessment, 2020
Table 14: Takeda’s Disease Portfolio Assessment, 2020
Table 15: UCB’s Disease Portfolio Assessment, 2020
Table 16: Genentech’s Disease Portfolio Assessment, 2020
Table 17: Eli Lilly’s Disease Portfolio Assessment, 2020
Table 18: AstraZeneca’s Disease Portfolio Assessment, 2020
Table 19: BMS’s Disease Portfolio Assessment, 2020
Table 20: Galapagos’ Disease Portfolio Assessment, 2020
Table 21: Arena Pharmaceuticals’ Disease Portfolio Assessment, 2020
Table 22: RedBill Biopharma’s Disease Portfolio Assessment, 2020
Table 23: Crohn’s Disease Market - Global Drivers and Barriers, 2019-2029
Table 24: Key Events Impacting Sales for Crohn’s Disease in the US, 2019-2029
Table 25: Crohn’s Disease Market - Drivers and Barriers in the US, 2019-2029
Table 26: Key Events Impacting Sales for Crohn’s Disease in the 5EU, 2019-2029
Table 27: Crohn’s Disease Market - Drivers and Barriers in the 5EU, 2019-2029
Table 28: Key Events Impacting Sales for Crohn’s Disease in Japan, 2019-2029
Table 29: Crohn’s Disease Market - Global Drivers and Barriers in Japan, 2019-2029
Table 30: Key Events Impacting Sales for Crohn’s Disease in the Canada, 2019-2029
Table 31: Crohn’s Disease Market - Global Drivers and Barriers in Canada, 2019-2029
Table 32: Key Historical and Projected Launch Dates for Crohn’s Disease
Table 33: Key Historical and Projected Patent Expiry Dates for Crohn’s Disease
Table 34: High-Prescribing Physicians (non-KOLs) Surveyed, By Country